Loading, Please Wait...
CAMBRIDGE, Mass., May 20, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will present interim data from the ongoing Phase 1 dose-escalation study evaluating XMT-1536, its first-in-class ADC candidate targeting NaPi2b, in patients with ovarian cancer, non-small cell lung (NSCLC) adenocarcinoma and other rare tumor types. The data will be presented in a poster session and poster discussion at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting being held from May 31 – June 4, 2019 in Chicago, IL.
Details of the poster display and discussion are as follows:
Poster Title: Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b.
Abstract Number: 3010
Date: June 1, 2019
Poster Display: 8:00 AM – 11:00 AM C.T., Location – Hall A, Poster Board #2
Poster Discussion: 3:00 PM – 3:22 PM C.T., Location – E450
Session: Developmental Therapeutics and Tumor Biology (Nonimmuno)
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms and its modular Synthemer scaffold to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana’s lead product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC adenocarcinoma, and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.
Sarah Carmody, 617-844-8577
Paul Kidwell, 617-680-1088